We propose to test the hypothesis that IL-23 mediates a destructive inflammatory response to C. difficile infection (CDI). We further hypothesize in Aim 1 that inflammatory dendritic cells (DCs) produce IL-23 in the colon, and (Aim 2) that IL-23 in turn causes inflammation that disrupts the gut epithelial barrier, and that (Aim 3) the targets of IL-23 action are IL-23R expressing innate lymphoid cells (ILCs) that produce IL-17, IL- 22, and/ or IFN?. Successful completion of these studies will delineate the mechanism and pathways of IL-23 mediated exacerbation of CDI and provide several potential sites for therapeutic intervention. Significance: C. difficile is the number one hospital-acquired infection in North America and despite antibiotic therapy has a mortality of 10-15%, with relapses in 10-35% of patients. Innovative aspects of the proposal include that it explores the potential for immune modulators in the treatment of C. difficile. The environment for the work includes a team of graduate students in the lab of the Principal Investigator who has contributed to infectious colitis research for over 25 years, and an external advisor, Dr. Brian Kelsall, who brings special expertise in dendritic cell biology. R21: The scope is appropriate for an R21 as the work is at the earliest conceptual stages of understanding of IL-23 in CDI, and proposes a high risk/high reward study of its mechanisms of action.

Public Health Relevance

Clostridium difficile is the most common cause of hospital-acquired diarrhea in the US. The CDC in 2013 named it as one of the three 'Urgent Threats' (the highest CDC threat level) because it is of increasing prevalence, and because up to 15% of patients with C. difficile die and 20% relapse despite antibiotic therapy. We propose to identify the mechanism by which IL-23 worsens C. difficile disease and thereby provide new approaches of combined anti-inflammatory and antibiotic therapy for this life-threatening infection.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
1R21AI114734-01
Application #
8793955
Study Section
Gastrointestinal Mucosal Pathobiology Study Section (GMPB)
Program Officer
Ranallo, Ryan
Project Start
2015-05-01
Project End
2017-04-30
Budget Start
2015-05-01
Budget End
2016-04-30
Support Year
1
Fiscal Year
2015
Total Cost
$230,926
Indirect Cost
$80,926
Name
University of Virginia
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
065391526
City
Charlottesville
State
VA
Country
United States
Zip Code
22904
Cowardin, Carrie A; Jackman, Brianna M; Noor, Zannatun et al. (2016) Glucosylation Drives the Innate Inflammatory Response to Clostridium difficile Toxin A. Infect Immun 84:2317-2323
Steele, Shaun P; Melchor, Stephanie J; Petri Jr, William A (2016) Tuft Cells: New Players in Colitis. Trends Mol Med 22:921-924
Cowardin, Carrie A; Buonomo, Erica L; Saleh, Mahmoud M et al. (2016) The binary toxin CDT enhances Clostridium difficile virulence by suppressing protective colonic eosinophilia. Nat Microbiol 1:16108
Buonomo, Erica L; Cowardin, Carrie A; Wilson, Madeline G et al. (2016) Microbiota-Regulated IL-25 Increases Eosinophil Number to Provide Protection during Clostridium difficile Infection. Cell Rep 16:432-443
Buonomo, Erica L; Petri Jr, William A (2016) The microbiota and immune response during Clostridium difficile infection. Anaerobe 41:79-84